| Variable | Northwest Territories | Nunavut | Nunavut without Iqaluit | Kitikmeot | Kivalliq | Qikiqtaaluk | Qikiqtaaluk without Iqaluit | Nunavik |
|---|---|---|---|---|---|---|---|---|
| Total births in 2009 | 739 | 816 | 701 | 114 | 245 | 457 | 342 | 250 |
| Healthy newborns | 679.9 | 750.7 | 644.9 | 104.9 | 225.4 | 420.4 | 314.6 | 230 |
| Estimated rate of RSV-related admissions per 1000 population at risk† | 16.6 | 97.8 | 111.6 | 296.1 | 112.7 | 40.3 | 49.4 | 184.1 |
| Base case: no prophylaxis, RSV-related admissions in healthy term infants | ||||||||
| Total no. of RSV-related admissions documented in 2009 in healthy term infants | 8 | 52 | 51 | 22 | 18 | 12 | 11 | 30 |
| Total cost of admissions, $ | 177 256 | 2 871 137 | 2 856 561 | 1 496 365 | 1 094 603 | 280 169 | 265 593 | 632 139 |
| Scenario C: universal palivizumab prophylaxis of healthy term infants, with 88% risk reduction | ||||||||
| Total no. of RSV-related admissions | 0.96 | 6.24 | 6.12 | 2.64 | 2.16 | 1.44 | 1.32 | 3.6 |
| Total costs of RSV-related admissions, $ | 21 271 | 344 536 | 342 787 | 179 564 | 131 352 | 33 620 | 31 871 | 75 857 |
| Estimated cost of palivizumab, $ | 5 009 170 | 5 653 859 | 4 874 975 | 840 427 | 1 708 285 | 3 105 148 | 2 326 264 | 1 720 849 |
| Total costs (palivizumab + RSV-related admissions), $ | 5 030 441 | 5 998 395 | 5 217 762 | 1 019 991 | 1 839 637 | 3 138 768 | 2 358 135 | 1 796 706 |
| Scenario C v. base case | ||||||||
| Incremental cost for RSV prophylaxis, $ | 4 853 185 | 3 127 259 | 2 361 202 | -476 374 | 745 035 | 2 858 599 | 2 092 542 | 1 164 566 |
| Incremental RSV-related admissions avoided | 7.0 | 45.8 | 44.9 | 19.4 | 15.8 | 10.6 | 9.7 | 26.4 |
| ICER per RSV-related admission avoided, $ | 714 580 | 69 087 | 52 898 | -26 877 | 47 201 | 277 275 | 221 724 | 44 976 |
| NNT to prevent 1 RSV-related admission | 77.2 | 13.1 | 11.5 | 4.3 | 11.4 | 31.8 | 26.0 | 7.0 |
Note: ICER = incremental cost-effectiveness ratio, NNT = number needed to treat, RSV = respiratory syncytial virus.